About Issar Pharmaceuticals
Issar Pharmaceuticals is a company based in Hyderabad (India) founded in 1995. Issar Pharmaceuticals has raised $3.83 million across 1 funding round. Issar Pharmaceuticals offers products and services including Novoskin®, Xylentra®, IS-107, and IS-217. Issar Pharmaceuticals operates in a competitive market with competitors including Incyte, LEO Pharma, TScan Therapeutics, Formation Bio and Lyell Immunopharma, among others.
- Headquarter Hyderabad, India
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Issar Pharmaceuticals Pvt. Ltd.
- Jurisdiction Hyderabad, Telangana, India
-
Annual Revenue
$61.01 K (USD)-98.03as on Mar 31, 2022
-
Net Profit
-$86.45 K (USD)-105.85as on Mar 31, 2022
-
EBITDA
-$771.99 K (USD)-136as on Mar 31, 2022
-
Total Equity Funding
$3.83 M (USD)
in 1 rounds
-
Latest Funding Round
$3.83 M (USD), Series A
Feb 10, 2019
-
Investors
Not available
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Issar Pharmaceuticals
Issar Pharmaceuticals offers a comprehensive portfolio of products and services, including Novoskin®, Xylentra®, IS-107, and IS-217.
Peptide-based solution for vitiligo skin conditions.
Topical product for effective wound healing applications.
Injectable therapy targeting solid tumor treatments.
Injectable for psoriasis and related skin disorders.
Funding Insights of Issar Pharmaceuticals
Issar Pharmaceuticals has successfully raised a total of $3.83M through 1 strategic funding round. The most recent funding activity was a Series A round of $3.83 million completed in February 2019. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investments & Acquisitions by Issar Pharmaceuticals
Investment portfolio details for Issar Pharmaceuticals
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Issar Pharmaceuticals
Detailed financials for Issar Pharmaceuticals
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Issar Pharmaceuticals Comparisons
Peer comparison for Issar Pharmaceuticals
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Issar Pharmaceuticals
Issar Pharmaceuticals operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Incyte, LEO Pharma, TScan Therapeutics, Formation Bio and Lyell Immunopharma, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Small molecules are developed for cancer and skin disease treatments.
|
|
| Locked | Locked | Locked |
Developer of drugs for treating dermatology diseases
|
|
| Locked | Locked | Locked |
T cell-based treatments for immunological and oncological disorders are developed.
|
|
| Locked | Locked | Locked |
AI-powered drug discovery platform for various diseases
|
|
| Locked | Locked | Locked |
CAR-T and TIL immunotherapies for solid tumors are developed.
|
|
| Locked | Locked | Locked |
Antibody drugs for cancer treatment are developed.
|
Detailed competitors of Issar Pharmaceuticals
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Issar Pharmaceuticals
Complete news archive for Issar Pharmaceuticals
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Issar Pharmaceuticals
Issar Pharmaceuticals was founded in 1995 and raised its 1st funding round 24 years after it was founded.
Issar Pharmaceuticals is headquartered in Hyderabad, India. It is registered at Hyderabad, Telangana, India.
Issar Pharmaceuticals is a funded company, having raised a total of $3.83M across 1 funding round to date.
Annual revenue of Issar Pharmaceuticals is $61.01K as on Mar 31, 2022.
Issar Pharmaceuticals is a developer of peptide-based therapeutic products to treat multiple diseases. The company has developed melgain which is a topical product used for vitiligo (market phase). The other pipeline products include Xylentra, a drug for wound treatment in clinical trial phase 3 with US-FDA in the preclinical stage, IS-217 drug for solid tumors (phase I), and psoriasis (US-FDA in preclinical stage). The preclinical pipeline includes drugs in the preclinical stage for inflammatory bowel disease, sepsis rheumatoid arthritis, and atopic dermatitis.
Issar Pharmaceuticals's top competitors include Hummingbird Bioscience, Lyell Immunopharma and LEO Pharma.
Issar Pharmaceuticals offers Novoskin®, Xylentra®, IS-107, and IS-217.